APAnne K. Penttilä

Anne K. Penttilä

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anne K. Penttilä has a total of 81 co-authors. Here are the top co-authors by number of shared publications:

  • Anne Juuti

    Helsinki University Hospital and University of Helsinki

    5 shared publications
  • Henna Sammalkorpi

    Helsinki University Hospital and University of Helsinki

    4 shared publications
  • Hannele Yki-Järvinen

    Department of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

    3 shared publications
  • Panu K. Luukkonen

    Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Sciences (HiLife), University of Helsinki, Helsinki, Finland; Department of Internal Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Minerva Foundation Institute for Medical Research, Helsinki, Finland; Transplantation and Liver Surgery, Abdominal Center, Helsinki University Hospital, Helsinki, Finland

    3 shared publications
  • Sami Qadri

    Department of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

    3 shared publications
  • Antti Hakkarainen

    HUS Medical Imaging Center, Helsinki University Hospital, Helsinki, Finland

    2 shared publications

Latest Publications

  • Changes in body composition and resting energy expenditure during the first year after Roux-en-Y or one-anastomosis gastric bypass

    by Jari E. Karppinen, Sini Heinonen, Tuure Saarinen, Birgitta W. van der Kolk, Ulla Säiläkivi, Henna Sammalkorpi, Anne K. Penttilä, Per-Henrik Groop, Anne Juuti, Kirsi H. Pietiläinen

    Resting energy expenditure declines after bariatric surgery, but the relative roles of tissue loss and adaptive thermogenesis are unclear. Using DXA-based organ-tissue estimates with indirect calorimetry, we show that adaptive thermogenesis accounted for ∼44% of the 6-mo postoperative REE decline, with the remainder due to tissue loss. Adaptive thermogenesis was not robustly detectable at 12 mo. Roux-en-Y and one-anastomosis gastric bypass show similar body composition and REE changes.


  • Open Access

    Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease

    by Sami Qadri, Noora Ahlholm, Ida Lønsmann, Paola Pellegrini, Anni Poikola, Panu K Luukkonen, Kimmo Porthan, Anne Juuti, Henna Sammalkorpi, Anne K Penttilä, et al.

    Context Guidelines recommend blood-based fibrosis biomarkers to identify advanced nonalcoholic fatty liver disease (NAFLD), which is particularly prevalent in patients with obesity. Objective To study whether the degree of obesity affects the performance of liver fibrosis biomarkers in NAFLD. Design Cross-sectional cohort study comparing simple fibrosis scores [Fibrosis-4 Index (FIB-4); NAFLD Fibrosis Score (NFS); aspartate aminotransferase to platelet ratio index; BARD (body mass index, aspartate-to-alanine aminotransferase ratio, diabetes); Hepamet Fibrosis Score (HFS)] and newer scores incorporating neo-epitope biomarkers PRO-C3 (ADAPT, FIBC3) or cytokeratin 18 (MACK-3). Setting Tertiary referral center. Patients We recruited overweight/obese patients from endocrinology (n = 307) and hepatology (n = 71) clinics undergoing a liver biopsy [median body mass index (BMI) 40.3 (interquartile range 36.0-44.7) kg/m2]. Additionally, we studied 859 less obese patients with biopsy-proven NAFLD to derive BMI-adjusted cutoffs for NFS. Main Outcome Measures Biomarker area under the receiver operating characteristic (AUROC), sensitivity, specificity, and predictive values to identify histological stage ≥F3 fibrosis or nonalcoholic steatohepatitis with ≥F2 fibrosis [fibrotic nonalcoholic steatohepatitis (NASH)]. Results The scores with an AUROC ≥0.85 to identify ≥F3 fibrosis were ADAPT, FIB-4, FIBC3, and HFS. For fibrotic NASH, the best predictors were MACK-3 and ADAPT. The specificities of NFS, BARD, and FIBC3 deteriorated as a function of BMI. We derived and validated new cutoffs for NFS to rule in/out ≥F3 fibrosis in groups with BMIs 2. This optimized its performance at all levels of BMI. Sequentially combining FIB-4 with ADAPT or FIBC3 increased specificity to diagnose ≥F3 fibrosis. Conclusions In obese patients, the best-performing fibrosis biomarkers are ADAPT and the inexpensive FIB-4, which are unaffected by BMI. The widely used NFS loses specificity in obese individuals, which may be corrected with BMI-adjusted cutoffs.


  • The PNPLA3-I148M Variant Confers an Antiatherogenic Lipid Profile in Insulin-resistant Patients

    by Panu K Luukkonen, Sami Qadri, Tiina E Lehtimäki, Anne Juuti, Henna Sammalkorpi, Anne K Penttilä, Antti Hakkarainen, Marju Orho-Melander, Johanna Arola, Hannele Yki-Järvinen

    Context: The I148M (rs738409-G) variant in PNPLA3 increases liver fat content but may be protective against cardiovascular disease. Insulin resistance (IR) amplifies the effect of PNPLA3-I148M on liver fat.Objective: To study whether PNPLA3-I148M confers an antihyperlipidemic effect in insulin-resistant patients.Design: Cross-sectional study comparing the impact of PNPLA3-I148M on plasma lipids and lipoproteins in 2 cohorts, both divided into groups based on rs738409-G allele carrier status and median HOMA-IR.Setting: Tertiary referral center.Patients: A total of 298 obese patients who underwent a liver biopsy during bariatric surgery (bariatric cohort: age 49 ± 9 years, body mass index [BMI] 43.2 ± 6.8 kg/m2), and 345 less obese volunteers in whom liver fat was measured by proton magnetic resonance spectroscopy (nonbariatric cohort: age 45 ± 14 years, BMI 29.7 ± 5.7 kg/m2).Main Outcome Measures: Nuclear magnetic resonance profiling of plasma lipids, lipoprotein particle subclasses and their composition.Results: In both cohorts, individuals carrying the PNPLA3-I148M variant had significantly higher liver fat content than noncarriers. In insulin-resistant and homozygous carriers, PNPLA3-I148M exerted a distinct antihyperlipidemic effect with decreased very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) particles and their constituents, and increased high-density lipoprotein particles and their constituents, compared with noncarriers. VLDL particles were smaller and LDL particles larger in PNPLA3-I148M carriers. These changes were geometrically opposite to those due to IR. PNPLA3-I148M did not have a measurable effect in patients with lower IR, and its effect was smaller albeit still significant in the less obese than in the obese cohort.Conclusions: PNPLA3-I148M confers an antiatherogenic plasma lipid profile particularly in insulin-resistant individuals.


  • Open Access

    The PNPLA3‐I148M variant increases polyunsaturated triglycerides in human adipose tissue

    by Sami Qadri, Susanna Lallukka‐Brück, Panu K. Luukkonen, You Zhou, Amalia Gastaldelli, Marju Orho‐Melander, Henna Sammalkorpi, Anne Juuti, Anne K. Penttilä, Julia Perttilä, et al.

    Background & Aims: The I148M variant in PNPLA3 is the major genetic risk factor for non‐alcoholic fatty liver disease (NAFLD). The liver is enriched with polyunsaturated triglycerides (PUFA‐TGs) in PNPLA3‐I148M carriers. Gene expression data indicate that PNPLA3 is liver‐specific in humans, but whether it functions in adipose tissue (AT) is unknown. We investigated whether PNPLA3‐I148M modifies AT metabolism in human NAFLD.Methods: Profiling of the AT lipidome and fasting serum non‐esterified fatty acid (NEFA) composition was conducted in 125 volunteers (PNPLA3148MM/MI, n = 63; PNPLA3148II, n = 62). AT fatty acid composition was determined in 50 volunteers homozygous for the variant (PNPLA3148MM, n = 25) or lacking the variant (PNPLA3148II, n = 25). Whole‐body insulin sensitivity of lipolysis was determined using [2H5]glycerol, and PNPLA3 mRNA and protein levels were measured in subcutaneous AT and liver biopsies in a subset of the volunteers.Results: PUFA‐TGs were significantly increased in AT in carriers versus non‐carriers of PNPLA3‐I148M. The variant did not alter the rate of lipolysis or the composition of fasting serum NEFAs. PNPLA3 mRNA was 33‐fold higher in the liver than in AT (P < .0001). In contrast, PNPLA3 protein levels per tissue protein were three‐fold higher in AT than the liver (P < .0001) and nine‐fold higher when related to whole‐body AT and liver tissue masses (P < .0001).Conclusions: Contrary to previous assumptions, PNPLA3 is highly abundant in AT. PNPLA3‐I148M locally remodels AT TGs to become polyunsaturated as it does in the liver, without affecting lipolysis or composition of serum NEFAs. Changes in AT metabolism do not contribute to NAFLD in PNPLA3‐I148M carriers.


  • Open Access

    Bile Reflux is a Common Finding in the Gastric Pouch After One Anastomosis Gastric Bypass

    by Tuure Saarinen, Kirsi H. Pietiläinen, Antti Loimaala, Toni Ihalainen, Henna Sammalkorpi, Anne Penttilä, Anne Juuti

    Introduction: Data on postoperative bile reflux after one anastomosis gastric bypass (OAGB) is lacking. Bile reflux scintigraphy (BRS) has been shown to be a reliable non-invasive tool to assess bile reflux after OAGB. We set out to study bile reflux after OAGB with BRS and endoscopy in a prospective series (RYSATrial).Methods: Forty patients (29 women) underwent OAGB between November 2016 and December 2018. Symptoms were reported and upper gastrointestinal endoscopy (UGE) was done preoperatively. Six months after OAGB, bile reflux was assessed in UGE findings and as tracer activity found in gastric tube and esophagus in BRS (follow-up rate 95%).Results: Twenty-six patients (68.4%) had no bile reflux in BRS. Twelve patients (31.6%) had bile reflux in the gastric pouch in BRS and one of them (2.6%) had bile reflux also in the esophagus 6 months postoperatively. Mean bile reflux activity in the gastric pouch was 5.2% (1–21%) of total activity. De novo findings suggestive of bile reflux (esophagitis, stomal ulcer, foveolar inflammation of gastric pouch) were found for 15 patients (39.5%) in postoperative UGE. BRS and UGE findings were significantly associated (P = 0.022). Eight patients experienced de novo reflux symptoms at 6 months, that were significantly associated with BRS and de novo UGE findings postoperatively (P = 0.033 and 0.0005, respectively).Conclusion: Postoperative bile reflux in the gastric pouch after OAGB is a common finding in scintigraphy and endoscopy. The long-term effects of bile exposure will be analyzed in future reports after a longer follow-up.Trial registration: Clinical Trials Identifier NCT02882685


  • A Retrospective 2-Year Follow-up of Late Complications Treated Surgically and Endoscopically After Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) and Laparoscopic Sleeve Gastrectomy (LSG) for Morbid Obesity

    by Mervi Javanainen, Anne Penttilä, Harri Mustonen, Anne Juuti, Tom Scheinin, Marja Leivonen

    The laparoscopic Roux-en-Y gastric bypass (LRYGB) has been the gold standard for bariatric surgery, but recently, the laparoscopic sleeve gastrectomy (LSG) has gained popularity. At present, limited data is available on the long-term complications of these two types of surgery. The aim of this retrospective study was to compare the 2-year data about late (more than 30 days after surgery) complications that were treated surgically or endoscopically after LRYGB and LSG operations in a large hospital area with a single patient database.


  • Open Access

    Interleukin 8 and hepatocyte growth factor in predicting development of severe acute pancreatitis

    by Anne K. Penttilä, Outi Lindström, Johanna Hästbacka, Krista Kuuliala, Harri Mustonen, Pauli Puolakkainen, Antti Kuuliala, Marko Salmi, Mari Hämäläinen, Eeva Moilanen, et al.

    Objectives: We aimed to study if interleukin (IL) 8 and hepatocyte growth factor (HGF) predict development of severe acute pancreatitis (SAP) among patients without organ dysfunction (OD) at presentation, and if they discriminate transient OD from persistent OD among patients presenting with OD. Methods: From prospectively collected cohort of 176 AP patients and 32 healthy controls, plasma levels of IL-8 and HGF were determined within 5 days after symptom onset using an enzyme-linked immunosorbent assay. Results: AP was severe in 23 patients, of whom 10 did not have clinical signs of OD at presentation. IL-8 and HGF levels increased along with the severity of AP (P < 0.001). In patients without OD at study entry, IL-8 and HGF values predicted the development of SAP with the AUCs of 0.73 (95% CI, 0.56–0.91) and 0.79 (95% CI, 0.66–0.93), respectively. Of all patients, 22 presented with OD, and among them IL-8 predicted persistence of OD with the AUC of 0.88 (95% CI 0.69–1.0). Combining IL-8 and HGF did not improve the models. Conclusions: In AP patients without OD at presentation, circulating levels of IL-8, or HGF, may predict the development of SAP. In patients presenting with OD, IL-8 level may discriminate the patients with transient OD from those with persistent OD.


  • Significant inter-observer variation in the diagnosis of extrapancreatic necrosis and type of pancreatic collections in acute pancreatitis – An international multicenter evaluation of the revised Atlanta classification

    by Hanna Sternby, Robert C. Verdonk, Guadalupe Aguilar, Alexandra Dimova, Povilas Ignatavicius, Lucas Ilzarbe, Peeter Koiva, Eila Lantto, Tonis Loigom, Anne Penttilä, et al.


  • Open Access

    Circulating nucleosomes as predictive markers of severe acute pancreatitis

    by Anne K. Penttilä, Ari Rouhiainen, Leena Kylänpää, Harri Mustonen, Pauli Puolakkainen, Heikki Rauvala, Heikki Repo

    The components of nucleosomes, which contain DNA and histones, are released into the circulation from damaged cells and can promote inflammation. We studied whether the on-admission levels of circulating nucleosomes predict the development of severe acute pancreatitis (AP), in particular among the patients who present without clinical signs of organ dysfunction. This is a prospective study of 74 AP patients admitted to Helsinki University Hospital from 2003 to 2007. Twenty-three patients had mild, 27 moderately severe, and 24 severe AP as defined by the revised Atlanta criteria. 14/24 severe AP patients had no sign of organ dysfunction on admission (modified marshall score <2). Blood samples were obtained on admission and the plasma levels of nucleosomes were measured using enzyme-linked immunosorbent assay. The on-admission levels of nucleosomes were significantly higher in severe AP than in mild or moderately severe AP (p < 0.001 for all), higher in non-survivors (n = 8) than in survivors (p = 0.019), and correlated with the on-admission levels of C-reactive protein (p < 0.001) and creatinine (p < 0.001). Among the AP patients who presented without organ dysfunction, the on-admission nucleosome level was an independent predictor of severe AP (p = 0.038, gender-adjusted forward-stepping logistic regression). Circulating nucleosome levels may be helpful in identifying, on admission to hospital, the AP patients who present without clinical signs of organ dysfunction, and, yet, are bound to develop organ dysfunction during hospitalization.